BridgeBio Oncology Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsBridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule inhibitors targeting RAS-pathway cancers.
What they do
The company is focused on discovering and developing therapies for KRAS-mutant cancers. Its pipeline includes BBO-8520 (KRAS G12C inhibitor), BBO-11818 (pan-KRAS inhibitor), and BBO-10203 (RAS-PI3Kα interaction blocker). These products are designed for both monotherapy and combination use, including internal combinations to suppress MAPK and PI3Kα pathways. As of mid-2026, the company was enrolling patients across several early-stage clinical trials.
Revenue drivers
- Product revenue — No approved products or product revenue; all candidates are in clinical development. The company is pre-revenue.
Recent performance
For Q2 2026, BBOT reported R&D expenses of $49.2 million (up from $27.4 million in Q2 2025) and G&A expenses of $11.0 million (up from $2.7 million), reflecting higher clinical trial and manufacturing costs and de-SPAC-related costs. The company had cash, cash equivalents, and marketable securities of $344.1 million as of June 30, 2026. Net loss for 2025 was $134.0 million, and operating cash flow was -$113.9 million. Total assets were $376.7 million and total liabilities were $53.6 million at June 30, 2026.
Strategy
The company is advancing three clinical programs—BBO-8520, BBO-11818, and BBO-10203—through monotherapy and combination cohorts. Its stated strategy is to achieve direct dual inhibition of KRAS G12C or G12D/V in both ON and OFF states, and to disrupt RAS-driven PI3Kα activation, enabling internal combination strategies. The company emphasizes combining these assets with standard-of-care regimens to maximize patient benefit. Management expects multiple clinical milestones in the second half of 2026.
Risks
- Clinical-stage risk — All product candidates are in early-stage trials and may fail to show safety or efficacy.
- No revenue — The company has no approved products and relies on funding; sustained operating losses are expected.
- Cash runway limited — Management expects cash to fund operations into 2028, but dependence on external financing is a risk.
- Competitive landscape — Other companies are developing KRAS-targeted therapies, and BBOT's candidates may face significant competition.
Outlook
Management expects to report multiple near-term clinical milestones across BBO-8520, BBO-11818, and BBO-10203 in the second half of 2026. The company has initiated or continues combination dosing for these programs, including BBO-11818 with cetuximab and with BBO-10203. Cash runway is projected into 2028.